摘要
目的探讨检测超敏C反应蛋白(hs-CRP)、白细胞介素6(IL-6)、降钙素原(PCT)对新型冠状病毒肺炎(COVID-19)患者预后评估的临床价值。方法选择150例COVID-19患者按诊断标准分为4组:轻型组(48例)、普通型组(45例)、重型组(35例)、危重型组(22例),测定各组患者血清hs-CRP、IL-6、PCT水平,并分析血清hs-CRP、IL-6、PCT水平对COVID-19患者预后评估以及对死亡风险的预测。结果对于血清hs-CRP、IL-6、PCT水平,危重型组>重型组>普通型组>轻型组,差异均有统计学意义(P<0.05)。随着患者病情的加重,APACHEII评分也逐渐升高,但差异无统计学意义。血清hs-CRP、IL-6、PCT三者联合检测对患者预后的判断强于单一项目。与存活组比较,死亡组的hs-CRP、IL-6、PCT明显升高,两组比较差异具有统计学意义(P<0.05)。血清hs-CRP、IL-6、PCT水平联合检测在预测COVID-19死亡风险的准确率大于单一项目(P<0.05),与APACHE II评分相差不大。结论血清hs-CRP、IL-6、PCT联合检测有助于判断COVID-19患者的预后,并且可以用来评估COVID-19患者的死亡风险。
Objective To explore the clinical value of detecting hs-CRP, interleukin 6(IL-6) and procalcitonin(PCT) in evaluating the prognosis of patients with COVID-19. Methods Patients(150 cases) with COVID-19 were divided into four groups according to diagnostic criteria: mild group(48 cases), normal group(45 cases), serious group(35 cases), and critical group(22 cases). The serum levels of hs-CRP, IL-6, and PCT were measured, serum levels of hs-CRP, IL-6, and PCT were analyzed to assess the prognosis of COVID-19 and to predict the risk of death. Results For the levels of hs-CRP, IL-6, and PCT, the critical group > serious group > normal group > mild group, with significant difference(P < 0.05). APACHE II score increased with the progression of COVID-19, but there was no significant difference. The combined detection of hs-CRP, IL-6, and PCT was more effective than the single item in predicting the prognosis of patients. Compared with the survival group, hs-CRP, IL-6, and PCT in death group were significantly increased(P < 0.05). The accuracy in predicting the risk of death from COVID-19 of the combined detection of hs-CRP, IL-6, and PCT was more than the detection of single item(P < 0.05), and similar to that of APACHE II. Conclusion The combination of serum hs-CRP, IL-6, and PCT can be used to predict the prognosis of patients with COVID-19 and to assess the risk of death in patients with COVID-19.
作者
昌仲勇
杨为斌
王强
廖国林
CHANG Zhong-yong;YANG Wei-bin;WANG Qiang;LIAO Guo-lin(Department of Clinical Laboratory,Wuhan Puren Hospital,Wuhan 430081,China)
出处
《现代药物与临床》
CAS
2020年第3期417-420,共4页
Drugs & Clinic
